Supplementation with a formulation rich in antioxidant compounds (the AREDS/AREDS 2 formulations) is often recommended for early stage AMD [18], whilst treatment is only possible for nvAMD using biologicals that inhibit vascular endothelial growth factor (VEGF), a key mediator of angiogenesis. The gene discussed is VEGFA; the disease is age-related macular degeneration.